AR079131A1 - Derivados de naftiridina y el uso de los mismos como inhibidores de quinasa - Google Patents
Derivados de naftiridina y el uso de los mismos como inhibidores de quinasaInfo
- Publication number
- AR079131A1 AR079131A1 ARP100104323A ARP100104323A AR079131A1 AR 079131 A1 AR079131 A1 AR 079131A1 AR P100104323 A ARP100104323 A AR P100104323A AR P100104323 A ARP100104323 A AR P100104323A AR 079131 A1 AR079131 A1 AR 079131A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- aryl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B55/00—Racemisation; Complete or partial inversion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Moduladores de quinasa del tipo de la naftiridina y preparacion y uso de los mismos como medicamentos para la modulacion de procesos de transduccion de la senal celular mal dirigida, en particular para influir sobre la funcion de las tirosina y serina/treonina quinasas y para el tratamiento de tumores malignos o benignos y otros trastornos basados en la proliferacion celular patologica, tales como, por ejemplo, restenosis, psoriasis, arteriosclerosis y cirrosis hepática. Reivindicacion 1: Derivados de naftiridina caracterizados porque son de la formula general (1) en la cual los sustituyentes R1-R6 tienen el siguiente significado R1, R2 y R3 pueden, independientemente entre sí, ser hidrogeno, alquilo no sustituido o sustituido, heterociclo no sustituido o sustituido, arilo no sustituido o sustituido, heteroarilo no sustituido o sustituido, halogeno, ciano, hidroxilo, alcoxi, amino, carboxilo, alcoxicarbonilo, carboxialquilo o alcoxicarbonilalquilo, alcoxicarbonilamino, alcoxicarbonilaminoalquilo, y NR7R8, donde al menos uno de los sustituyentes R1-R3 tiene que ser un NR7R8 y donde R7 puede ser H, alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquilcicloalquilo, alquilheterociclilo, alquilarilo o alquilheteroarilo, y los sustituyentes alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, alquilcicloalquilo, alquilheterociclilo, alquilarilo o alquilheteroarilo pueden, por su parte, estar sustituidos, y R8 puede ser: -C(Y)NR9R10, donde Y es O, S y R9 y R10 puede ser independientemente entre sí hidrogeno, alquilo no sustituido o sustituido, cicloalquilo no sustituido o sustituido, heterociclo no sustituido o sustituido, arilo no sustituido o sustituido, heteroarilo no sustituido o sustituido, o R9 y R10 juntos pueden ser heterociclilo, -C(Y)NR11R12, donde Y es NH y R11 y R12 puede ser independientemente entre si: H, alquilo no sustituido o sustituido, cicloalquilo no sustituido o sustituido, heterociclo no sustituido o sustituido, arilo no sustituido o sustituido, heteroarilo no sustituido o sustituido, o R11 y R12 juntos pueden ser heterociclilo, -C(NR13)R14 donde R13 es H y R14 puede ser alquilo no sustituido o sustituido, cicloalquilo no sustituido o sustituido, heterociclo no sustituido o sustituido, arilo no sustituido o sustituido, heteroarilo no sustituido o sustituido, R4, R5 y R6 puede ser independientemente entre sí: H, alquilo no sustituido o sustituido, cicloalquilo no sustituido o sustituido, heterociclo no sustituido o sustituido, arilo no sustituido o sustituido, heteroarilo no sustituido o sustituido, halogeno, ciano, hidroxilo, alcoxi, NR15R16, donde R15 y R16 pueden, independientemente entre sí, ser hidrogeno, alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquilciclilo, alquilheterociclilo, alquilarilo o alquilheteroarilo, y los sustituyentes alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, alquilcicloalquilo, alquilheterociclilo, alquilarilo o alquilheteroarilo pueden, por su parte, estar sustituidos, o R15 y R16 son juntos heterociclilo, donde heterociclilo puede, por su parte, en cambio estar sustituido, OR17, donde R17 puede ser alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquilcicloalquilo, alquilheterociclilo, alquilarilo o alquilheteroarilo, y los sustituyentes alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquilcicloalquilo, alquilheterociclilo, alquilarilo o alquilheteroarilo pueden, por su parte, en cambio estar sustituidos, SR18, donde R18 puede ser alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquilcicloalquilo, alquilheterociclilo, alquilarilo o alquilheteroarilo, y los sustituyentes alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, alquilcicloalquilo, alquilheterociclilo, alquilarilo o alquilheteroarilo pueden, por su parte, estar sustituidos, donde al menos uno de los sustituyentes R4-R6 tiene que ser un (hetero)arilo no sustituido o sustituido o NR15R16, sus sales aceptables fisiologicamente, hidratos, solvatos, donde los compuestos de la formula general (1) y sus sales, hidratos o solvatos puede encontrarse en forma de sus racematos, enantiomeros y/o diastereomeros, o en forma de mezclas de los enantiomeros y/o diastereomeros, en forma de los tautomeros y sus formas polimorficas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09177132A EP2332939A1 (en) | 2009-11-26 | 2009-11-26 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors |
| US26471109P | 2009-11-27 | 2009-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079131A1 true AR079131A1 (es) | 2011-12-28 |
Family
ID=41793139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104323A AR079131A1 (es) | 2009-11-26 | 2010-11-24 | Derivados de naftiridina y el uso de los mismos como inhibidores de quinasa |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8461178B2 (es) |
| EP (2) | EP2332939A1 (es) |
| JP (1) | JP5726202B2 (es) |
| KR (1) | KR20120096545A (es) |
| CN (1) | CN102666536B (es) |
| AR (1) | AR079131A1 (es) |
| AU (1) | AU2010323137B2 (es) |
| BR (1) | BR112012012694A2 (es) |
| CA (1) | CA2781818A1 (es) |
| ES (1) | ES2573665T3 (es) |
| IL (1) | IL219646A0 (es) |
| MX (1) | MX345495B (es) |
| NZ (1) | NZ600042A (es) |
| PH (1) | PH12012500921A1 (es) |
| PL (1) | PL2504336T3 (es) |
| RU (1) | RU2573390C2 (es) |
| TW (1) | TWI508963B (es) |
| WO (1) | WO2011064250A1 (es) |
| ZA (1) | ZA201202906B (es) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| WO2013018733A1 (ja) | 2011-07-29 | 2013-02-07 | 富士フイルム株式会社 | １，５－ナフチリジン誘導体又はその塩 |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| CN103183674B (zh) * | 2011-12-31 | 2017-09-12 | 江苏先声药业有限公司 | 一类稠杂环衍生物及其应用 |
| MX366983B (es) | 2012-01-19 | 2019-08-01 | Oncotherapy Science Inc | Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen. |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| NZ702747A (en) | 2012-06-13 | 2017-03-31 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| EP2944637B1 (en) | 2013-01-11 | 2020-02-19 | FUJIFILM Corporation | Nitrogen-containing heterocylic compound or salt thereof |
| LT2986610T (lt) * | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| AU2015238305B2 (en) | 2014-03-26 | 2020-06-18 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| SMT202100115T1 (it) | 2014-03-26 | 2021-05-07 | Astex Therapeutics Ltd | Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| SG10201913036RA (en) | 2015-02-20 | 2020-02-27 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3353164B1 (en) | 2015-09-23 | 2021-11-03 | Janssen Pharmaceutica, N.V. | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
| WO2017050864A1 (en) | 2015-09-23 | 2017-03-30 | Janssen Pharmaceutica Nv | New compounds |
| BR112018013977A2 (pt) * | 2016-01-11 | 2018-12-11 | Merck Patent Gmbh | derivados de quinolin-2-ona |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| EP4309737A3 (en) | 2018-05-04 | 2024-03-27 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
| EP3788046B1 (en) | 2018-05-04 | 2025-12-10 | Incyte Corporation | Salts of an fgfr inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| AR126101A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CN115806523B (zh) * | 2022-11-24 | 2024-11-22 | 贵州医科大学 | 一种取代喹啉化合物及其在制备抗肿瘤药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2650826A1 (de) | 1976-11-06 | 1978-05-11 | Merck Patent Gmbh | Cephemderivate |
| DE69906960T2 (de) | 1998-05-08 | 2004-01-29 | Smithkline Beecham Plc | Phenylurea und phenylthio urea derivate |
| GB9822440D0 (en) | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
| JP2002535323A (ja) | 1999-01-20 | 2002-10-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | プロテインキナーゼ阻害剤としてのピペリジニルキノリン |
| DE60009888T2 (de) | 1999-04-21 | 2005-04-21 | Wyeth Corp | Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen |
| GB9917408D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
| NZ523749A (en) | 2000-07-26 | 2005-03-24 | Smithkline Beecham P | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| US7405299B2 (en) * | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
| DE102004041163A1 (de) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| JP2010528114A (ja) | 2007-05-25 | 2010-08-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ |
| US20100179143A1 (en) | 2007-05-29 | 2010-07-15 | Smithkline Beecham Corporation | Naphthyridine, derivatives as p13 kinase inhibitors |
| GB0801416D0 (en) * | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| MX2010011663A (es) * | 2008-04-24 | 2011-01-21 | Abbott Gmbh & Co Kg | Derivados de 1-(7-hexahidropirrolo [3,4-c] pirrol-2 (1h)-il) quinolin-3-il)-(pirazin-2-il) urea y compuestos relacionados como glicogeno sintasa quinasa 3 (gsk-3). |
-
2009
- 2009-11-26 EP EP09177132A patent/EP2332939A1/en not_active Withdrawn
-
2010
- 2010-11-24 PL PL10782280.1T patent/PL2504336T3/pl unknown
- 2010-11-24 AU AU2010323137A patent/AU2010323137B2/en not_active Ceased
- 2010-11-24 PH PH1/2012/500921A patent/PH12012500921A1/en unknown
- 2010-11-24 EP EP10782280.1A patent/EP2504336B1/en active Active
- 2010-11-24 WO PCT/EP2010/068119 patent/WO2011064250A1/en not_active Ceased
- 2010-11-24 CN CN201080053354.2A patent/CN102666536B/zh not_active Expired - Fee Related
- 2010-11-24 NZ NZ600042A patent/NZ600042A/en not_active IP Right Cessation
- 2010-11-24 JP JP2012540415A patent/JP5726202B2/ja not_active Expired - Fee Related
- 2010-11-24 MX MX2012006154A patent/MX345495B/es active IP Right Grant
- 2010-11-24 AR ARP100104323A patent/AR079131A1/es unknown
- 2010-11-24 KR KR1020127016411A patent/KR20120096545A/ko not_active Abandoned
- 2010-11-24 RU RU2012120288/04A patent/RU2573390C2/ru not_active IP Right Cessation
- 2010-11-24 CA CA2781818A patent/CA2781818A1/en not_active Abandoned
- 2010-11-24 TW TW099140552A patent/TWI508963B/zh not_active IP Right Cessation
- 2010-11-24 US US12/953,680 patent/US8461178B2/en not_active Expired - Fee Related
- 2010-11-24 ES ES10782280.1T patent/ES2573665T3/es active Active
- 2010-11-24 BR BR112012012694A patent/BR112012012694A2/pt not_active IP Right Cessation
-
2012
- 2012-05-04 ZA ZA2012/02906A patent/ZA201202906B/en unknown
- 2012-05-08 IL IL219646A patent/IL219646A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011064250A1 (en) | 2011-06-03 |
| IL219646A0 (en) | 2012-07-31 |
| AU2010323137A1 (en) | 2012-06-07 |
| KR20120096545A (ko) | 2012-08-30 |
| EP2504336B1 (en) | 2016-03-30 |
| TW201121972A (en) | 2011-07-01 |
| JP2013512217A (ja) | 2013-04-11 |
| CN102666536B (zh) | 2016-03-30 |
| ES2573665T3 (es) | 2016-06-09 |
| PH12012500921A1 (en) | 2016-06-10 |
| ZA201202906B (en) | 2012-12-27 |
| EP2504336A1 (en) | 2012-10-03 |
| NZ600042A (en) | 2014-05-30 |
| CA2781818A1 (en) | 2011-06-03 |
| EP2332939A1 (en) | 2011-06-15 |
| RU2573390C2 (ru) | 2016-01-20 |
| CN102666536A (zh) | 2012-09-12 |
| HK1170737A1 (zh) | 2013-03-08 |
| RU2012120288A (ru) | 2014-01-10 |
| PL2504336T3 (pl) | 2016-10-31 |
| JP5726202B2 (ja) | 2015-05-27 |
| TWI508963B (zh) | 2015-11-21 |
| MX2012006154A (es) | 2012-06-28 |
| US20110150831A1 (en) | 2011-06-23 |
| MX345495B (es) | 2017-02-02 |
| US8461178B2 (en) | 2013-06-11 |
| AU2010323137B2 (en) | 2014-04-10 |
| BR112012012694A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079131A1 (es) | Derivados de naftiridina y el uso de los mismos como inhibidores de quinasa | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| PE20140975A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR065901A1 (es) | Derivados de pirrolipirimidina | |
| PE20190811A1 (es) | Derivados de pirazolopirimidinas como inhibidor de quinasa | |
| AR042532A1 (es) | Compuestos de 5,8-dihidro-6h-pirido[2,3-d]pirimidin-7-ona | |
| ES2567567T3 (es) | Derivados de quinazolindiona, su preparación y sus aplicaciones terapéuticas | |
| CR11738A (es) | Compuestos de pirimidinona pirrolo 3-metil-2-imino fenil sustituidos como inhibidores bace-1, composiciones y su uso | |
| AR045462A1 (es) | DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS | |
| AR070995A1 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe | |
| ECSP066298A (es) | Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3) | |
| ECSP088598A (es) | Derivados de piridazinona | |
| CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| PE20091268A1 (es) | Derivados heterociclicos como inhibidores de pi3 quinasa | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR071925A1 (es) | Malonamidas como antagonistas de orexina | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| AR074052A1 (es) | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa | |
| AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
| AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
| AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| CO5630029A2 (es) | Derivados de indol e indolina sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |